Drug
Low Calorie
Low Calorie: highest development phase Post-Market, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| low calorie, low nitrogen parenteral nutrition for patient with NRS score 3 NCT00247338 | Post-Market | Gastrointestinal Neoplasms |
Latest
No recent events.
Follow Low Calorie on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.